


# Stabilis



## Hydrocortisone sodium succinate



Noms commerciaux

Actocortina	Espagne
Androcortil	Brésil
Corticina	Vénézuela
Cortop	Italie
Drosodin	Mexique
Efcortisol	Grande Bretagne
Extaden	Mexique
Flebocortid	Italie, Maroc, Mexique
Fridalit	Argentine, Pérou
Hialub	Chili
Hycort	Vénézuela
Hydrocort	France
Hydrocortison	Allemagne
Inotid	Mexique
Itrocsona	Colombie
Novocortil	Pérou
Solu Cortef	Afrique du sud, Arabie Saoudite, Australie, Belgique, Canada, Chili, Colombie, Croatie, Danemark, Emirats Arabes Unis, Etats Unis d'Amérique, Finlande, Grande Bretagne, Grèce, Islande, Italie, Luxembourg, Norvège, Pays bas, Portugal, Suède, Suisse
Sonatalis	Mexique
Stricort	Malaisie, Vénézuela



### Stabilité des solutions

Container	Material	Concentration	Temperature	Light	Time	Stability	Reference
		1 mg/ml	25°C		3		739
	RL	1 mg/ml	25°C		3		739
	EI B	1 mg/ml	25°C		24		739
	EI B	2 mg/ml	23°C		24		31
	EI B	2 mg/ml	4°C		48		31
PVC		1 mg/ml	25°C		2		2001

		1 mg/ml	7°C		15			2001
		1 mg/ml	7°C		15			2001
		50 mg/ml	25°C		15			2001
		50 mg/ml	5°C		120			2001
		10 mg/ml	25°C		3			2354
		10 mg/ml	5°C		21			2354
	EI B	2 mg/ml	23°C		24			31
	EI B	2 mg/ml	4°C		48			31



## Stabilité en mélange

	EI B	0,478 mg/ml	23°C		Methotrexate sodium : 0,0314 mg/ml Cytarabine : 0,484 mg/ml	48		1661
	EI B	0,467 mg/ml	23°C		Methotrexate sodium : 0,0581 mg/ml Cytarabine : 0,477 mg/ml	48		1661
	EI B	0,489 mg/ml	23°C		Methotrexate sodium : 0,0721 mg/ml Cytarabine : 0,479 mg/ml	48		1661
	EI B	0,478 mg/ml	4°C		Methotrexate sodium : 0,0314 mg/ml Cytarabine : 0,484 mg/ml	48		1661
	EI B	0,467 mg/ml	4°C		Methotrexate sodium : 0,0581 mg/ml Cytarabine : 0,477 mg/ml	48		1661
	EI B	0,489 mg/ml	4°C		Methotrexate sodium : 0,0721 mg/ml Cytarabine : 0,479 mg/ml	48		1661
		10 mg/ml	25°C		Metronidazole : 5 mg/ml	7		631
		10 mg/ml	5°C		Metronidazole : 5 mg/ml	12		631
		2 mg/ml	25°C		Methotrexate sodium : 1 mg/ml Cytarabine : 4,1 mg/ml	24		1028
		2,5 mg/ml	24-26°C		Methotrexate sodium : 3 mg/ml	24		4641
		4 mg/ml	24-26°C		Methotrexate sodium : 6 mg/ml	24		4641
	RL	2 mg/ml	25°C		Methotrexate sodium : 1 mg/ml Cytarabine : 4,1 mg/ml	24		1028
	EI B	2 mg/ml	25°C		Methotrexate sodium : 1 mg/ml Cytarabine : 4,1 mg/ml	24		1028



## Compatibilités

	Hydrocortisone sodium succinate : 1 mg/ml Aciclovir sodium : 5 mg/ml		336

		Hydrocortisone sodium succinate : 1 mg/ml Allopurinol sodium : 3 mg/ml		307
		Hydrocortisone sodium succinate : 1 mg/ml Amifostine : 10 mg/ml		3
		Hydrocortisone sodium succinate : 0,25 mg/ml Aminophylline : 0,625 mg/ml		1259
		Hydrocortisone sodium succinate : 2 mg/ml Amiodarone hydrochloride : 9 mg/ml		4698
		Hydrocortisone sodium succinate Amoxicillin sodium / clavulanic acid		3545
		Hydrocortisone sodium succinate : 1 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Hydrocortisone sodium succinate : 1 mg/ml Amsacrine : 1 mg/ml		253
		Hydrocortisone sodium succinate : 1 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Hydrocortisone sodium succinate : 50 mg/ml Argatroban : 1 mg/ml		1964
		Hydrocortisone sodium succinate : 1 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Hydrocortisone sodium succinate : 1 mg/ml Aztreonam : 40 mg/ml		99
		Hydrocortisone sodium succinate : 1 mg/ml Bivalirudin : 5 mg/ml		1713
		Hydrocortisone sodium succinate : 0.98 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
		Hydrocortisone sodium succinate : 1 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Hydrocortisone sodium succinate : 1 mg/ml Cefepime dihydrochloride : 40 mg/ml		4465
		Hydrocortisone sodium succinate : 1 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Hydrocortisone sodium succinate : 1 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Hydrocortisone sodium succinate : 1 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Hydrocortisone sodium succinate : 0.4 & 1.25 mg/ml Cimetidine hydrochloride : 3 mg/ml		211
		Hydrocortisone sodium succinate : 1 mg/ml Ciprofloxacin lactate : 2 mg/ml		4465
		Hydrocortisone sodium succinate : 1 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Hydrocortisone sodium succinate : 1 mg/ml Cisatracurium besylate : 2 mg/ml		4465
		Hydrocortisone sodium succinate : 1 mg/ml Cladribine : 0.015 mg/ml		1496
		Hydrocortisone sodium succinate : 125 mg/ml Cytarabine : 16 mg/ml		132
		Hydrocortisone sodium succinate : 1.9 mg/ml Defibrotide : 8 mg/ml		3728
		Hydrocortisone sodium succinate : 1 mg/ml Dexmedetomidine : 4 µg/ml		1712

		Hydrocortisone sodium succinate : 50 & 125 mg/ml Diltiazem hydrochloride : 1 mg/ml		198
		Hydrocortisone sodium succinate : 1 & 2 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Hydrocortisone sodium succinate : 50 & 125 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Hydrocortisone sodium succinate : 1 mg/ml Docetaxel : 0.9 mg/ml		1754
		Hydrocortisone sodium succinate : 1 mg/ml Dopamine hydrochloride : 0.8 mg/ml		738
		Hydrocortisone sodium succinate : 1 mg/ml Doripenem : 4,5 mg/ml		4465
		Hydrocortisone sodium succinate : 1 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Hydrocortisone sodium succinate : 2 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Hydrocortisone sodium succinate : 1 mg/ml Epinephrine hydrochloride : 128 µg/ml		4465
		Hydrocortisone sodium succinate : 0.01 mg/ml Ergotamine tartrate : 0.5 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 0.01 mg/ml Ergotamine tartrate : 0.5 mg/ml		1228
		Hydrocortisone sodium succinate : 0.01 mg/ml Ergotamine tartrate : 0.5 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Esmolol hydrochloride : 10 mg/ml		384
		Hydrocortisone sodium succinate : 1 mg/ml Esmolol hydrochloride : 10 mg/ml		3879
		Hydrocortisone sodium succinate : 1 mg/ml Esomeprazole sodium : 0,8 mg/ml		4465
		Hydrocortisone sodium succinate : 1 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Hydrocortisone sodium succinate : 125 mg/ml Famotidine		397
		Hydrocortisone sodium succinate : 1 mg/ml Famotidine : 2 mg/ml		215
		Hydrocortisone sodium succinate : 1 mg/ml Famotidine : 0.2 mg/ml		398
		Hydrocortisone sodium succinate : 1 mg/ml Fenoldopam mesylate : 80 µg/ml		1803
		Hydrocortisone sodium succinate : 1 mg/ml Filgrastim : 30 µg/ml		244
		Hydrocortisone sodium succinate : 50 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Hydrocortisone sodium succinate : 1 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Hydrocortisone sodium succinate : 50 mg/ml Furosemide : 1 mg/ml		1232
		Hydrocortisone sodium succinate : 50 mg/ml Gallium nitrate : 1 mg/ml		91
		Hydrocortisone sodium succinate : 1 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423

		Hydrocortisone sodium succinate : 1 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Hydrocortisone sodium succinate : 60 mg/ml	RL	4411
		Hydrocortisone sodium succinate : 50 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Hydrocortisone sodium succinate : 250 mg/ml Caffeine : 10 mg/ml		3964
		Hydrocortisone sodium succinate : 25.6 mg/ml		3379
		Hydrocortisone sodium succinate : 0,5 & 1 mg/ml Antithymocyte globulin (rabbit) : 0,2 & 0,3 mg/ml		1822
		Hydrocortisone sodium succinate : 50 mg/ml Bivalirudin : 5 mg/ml		1944
		Hydrocortisone sodium succinate Bleomycin sulfate		4154
		Hydrocortisone sodium succinate : 50 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Hydrocortisone sodium succinate : 2 mg/ml Cefotaxime sodium : 83.3 mg/ml		4254
		Hydrocortisone sodium succinate : 1 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Hydrocortisone sodium succinate : 50 mg/ml Ciprofloxacin lactate : 2 mg/ml		288
		Hydrocortisone sodium succinate : 0,98 mg/ml		4776
		Hydrocortisone sodium succinate : 1 mg/ml Ciprofloxacin lactate : 2 mg/ml		4550
		Hydrocortisone sodium succinate Cytarabine		3580
		Hydrocortisone sodium succinate Dacarbazine		3267
		Hydrocortisone sodium succinate : 10 mg/ml Diatrizoate meglumine : 283 mg/ml		1085
		Hydrocortisone sodium succinate Dimenhydrinate		2087
		Hydrocortisone sodium succinate : 50 mg/ml		939
		Hydrocortisone sodium succinate : 1 mg/ml Cladribine : 0.5 mg/ml		1496
		Hydrocortisone sodium succinate : 125 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Hydrocortisone sodium succinate : 50 mg/ml Foscarnet sodium : 24 mg/ml		73
		Hydrocortisone sodium succinate Heparin sodium		3540
		Hydrocortisone sodium succinate : 2 mg/ml Heparin sodium : 50 UI/ml		317
		Hydrocortisone sodium succinate : 1 mg/ml		301
		Hydrocortisone sodium succinate Dacarbazine		3605
		Hydrocortisone sodium succinate Daunorubicin hydrochloride		3604



<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Doripenem : 5 mg/ml		2262
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 125 mg/ml Heparin sodium : 100 UI/ml		132
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml		1415
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 2 mg/ml Acetylsalicylic acid lysinate : 10 mg/ml		4698
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Atropine sulfate : 0.5 mg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Atropine sulfate : 0.5 mg/ml	RL	1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Betamethasone sodium phosphate : 3 mg/ml	RL	1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Betamethasone sodium phosphate : 3 mg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Ceftobiprole medocartil sodium : 2 mg/ml	RL	2269
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Chlorpromazine hydrochloride : 25 mg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Chlorpromazine hydrochloride : 25 mg/ml	RL	1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Cyanocobalamine : 0.1 mg/ml	RL	1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Cyanocobalamine : 0.1 mg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Diphenhydramine hydrochloride : 50 mg/ml	RL	1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Diphenhydramine hydrochloride : 50 mg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Dopamine hydrochloride : 40 mg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Dopamine hydrochloride : 40 mg/ml	RL	1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Droperidol : 1.25 mg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Droperidol : 1.25 mg/ml	RL	1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Epinephrine hydrochloride : 100 µg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Epinephrine hydrochloride : 100 µg/ml	RL	1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Fentanyl citrate : 50 µg/ml	RL	1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Fentanyl citrate : 50 µg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Fluorouracil : 50 mg/ml		1228
<input checked="" type="checkbox"/>	Hydrocortisone sodium succinate : 1 mg/ml Fluorouracil : 50 mg/ml	RL	1228

		Hydrocortisone sodium succinate : 1 mg/ml Fosfomycin : 30 mg/ml		4055
		Hydrocortisone sodium succinate : 1 mg/ml Furosemide : 10 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 50 mg/ml	RL	4603
		Hydrocortisone sodium succinate : 1 mg/ml Furosemide : 10 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Hetastarch : 60 mg/ml		1721
		Hydrocortisone sodium succinate : 1 mg/ml Human albumin : 250 mg/ml		4465
		Hydrocortisone sodium succinate : 1 mg/ml Hydralazine hydrochloride : 20 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Hydralazine hydrochloride : 20 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 1 mg/ml Ibuprofen lysinate : 4 mg/ml		4465
		Hydrocortisone sodium succinate : 2 & 50 mg/ml Idarubicin hydrochloride : 1 mg/ml		491
		Hydrocortisone sodium succinate : 1 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Hydrocortisone sodium succinate : 10 mg/ml Iohexol : 300 mg I/ml	∅	1085
		Hydrocortisone sodium succinate : 10 mg/ml Ioxaglate : 320 mg I/ml	∅	1085
		Hydrocortisone sodium succinate : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Hydrocortisone sodium succinate : 1 mg/ml Isoprenaline hydrochloride : 0.2 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 1 mg/ml Isoprenaline hydrochloride : 0.2 mg/ml		1228
		Hydrocortisone sodium succinate : 125 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Hydrocortisone sodium succinate : 1 mg/ml Labetalol hydrochloride : 5 mg/ml		3879
		Hydrocortisone sodium succinate : 1 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Hydrocortisone sodium succinate : 1 mg/ml Levofloxacin : 5 mg/ml		4465
		Hydrocortisone sodium succinate : 1 mg/ml Levothyroxine : 0,4 µg/ml		4465
		Hydrocortisone sodium succinate : 1 mg/ml Linezolid : 2 mg/ml	∅	1925
		Hydrocortisone sodium succinate : 50 mg/ml Lorazepam : 0.33 mg/ml		186
		Hydrocortisone sodium succinate : 1 mg/ml Magnesium sulfate : 500 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Magnesium sulfate : 500 mg/ml	RL	1228
		Hydrocortisone sodium succinate Magnesium sulfate		3838

		Hydrocortisone sodium succinate : 1 mg/ml Melphalan : 0.1 mg/ml		169
		Hydrocortisone sodium succinate : 1 mg/ml Meropenem : 20 mg/ml		4465
		Hydrocortisone sodium succinate : 125 mg/ml Meropenem : 50 mg/ml		4319
		Hydrocortisone sodium succinate : 1 mg/ml Metoprolol tartrate : 0.4 mg/ml		3879
		Hydrocortisone sodium succinate : 10 mg/ml Metronidazole : 5 mg/ml		1035
		Hydrocortisone sodium succinate : 10 mg/ml Metronidazole : 5 mg/ml		631
		Hydrocortisone sodium succinate Metronidazole		3594
		Hydrocortisone sodium succinate : 1 mg/ml Midazolam hydrochloride : 2 mg/ml		4550
		Hydrocortisone sodium succinate : 50 mg/ml Midazolam hydrochloride : 5 mg/ml		186
		Hydrocortisone sodium succinate : 0.05 mg/ml Midazolam hydrochloride : 0.05 & 0.25 mg/ml		1888
		Hydrocortisone sodium succinate : 1 mg/ml Midazolam hydrochloride : 1 mg/ml		4550
		Hydrocortisone sodium succinate : 1 mg/ml Minocycline hydrochloride : 50 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 1 mg/ml Minocycline hydrochloride : 50 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Morphine sulfate : 15 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 1 mg/ml Morphine sulfate : 15 mg/ml		1228
		Hydrocortisone sodium succinate N-acetylcysteine : 200 mg/ml		3766
		Hydrocortisone sodium succinate : 125 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Hydrocortisone sodium succinate : 2 mg/ml Nefopam : 0,16 mg/ml		4698
		Hydrocortisone sodium succinate : 1 mg/ml Neostigmine methylsulfate : 0.5 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Neostigmine methylsulfate : 0.5 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 0.8 mg/ml Netilmicin sulfate : 3 mg/ml		1200
		Hydrocortisone sodium succinate : 2 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Hydrocortisone sodium succinate : 1 mg/ml Norepinephrine bitartrate : 0,128 mg/ml		4465
		Hydrocortisone sodium succinate : 1 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Hydrocortisone sodium succinate : 1 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Hydrocortisone sodium succinate : 1 mg/ml Oxacillin sodium : 100 mg/ml	RL	1228



		Hydrocortisone sodium succinate : 1 mg/ml Oxacillin sodium : 100 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Oxaliplatin : 0,5 mg/ml		1662
		Hydrocortisone sodium succinate : 1 mg/ml Oxytocin : 600 UI/ml	RL	1228
		Hydrocortisone sodium succinate : 1 mg/ml Oxytocin : 600 UI/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Paclitaxel : 1.2 mg/ml		248
		Hydrocortisone sodium succinate : 1 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Hydrocortisone sodium succinate Pantoprazole sodium		2090
		Hydrocortisone sodium succinate : 1 mg/ml Paracetamol : 10 mg/ml		4465
		Hydrocortisone sodium succinate : 125 mg/ml Paracetamol : 10 mg/ml		4742
		Hydrocortisone sodium succinate : 125 mg/ml Paracetamol : 10 mg/ml		3571
		Hydrocortisone sodium succinate : 2 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Hydrocortisone sodium succinate : 1 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Hydrocortisone sodium succinate : 1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Hydrocortisone sodium succinate : 1 mg/ml Procainamide hydrochloride : 100 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Procainamide hydrochloride : 100 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 1 mg/ml Prochlorperazine edysilate : 5 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 1 mg/ml Prochlorperazine edysilate : 5 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Promethazine hydrochloride : 50 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Promethazine hydrochloride : 50 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 1 mg/ml Propofol : 10 mg/ml		300
		Hydrocortisone sodium succinate : 1 mg/ml Propranolol hydrochloride : 1 mg/ml	RL	1228
		Hydrocortisone sodium succinate : 1 mg/ml Propranolol hydrochloride : 1 mg/ml		1228
		Hydrocortisone sodium succinate : 1 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
		Hydrocortisone sodium succinate Rocuronium bromide		3564
		Hydrocortisone sodium succinate : 125 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Hydrocortisone sodium succinate : 1 mg/ml Sargramostim : 10 µg/ml		335

	Hydrocortisone sodium succinate : 1 mg/ml Scopolamine hydrobromide : 0.86 mg/ml		1228	
	Hydrocortisone sodium succinate : 1 mg/ml Scopolamine hydrobromide : 0.86 mg/ml	RL	1228	
	Hydrocortisone sodium succinate : 250 mg/ml Sugammadex : 100 mg/ml		3372	
	Hydrocortisone sodium succinate : 1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801	
	Hydrocortisone sodium succinate : 50 mg/ml Tacrolimus : 1000 µg/ml		479	
	Hydrocortisone sodium succinate : 1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827	
	Hydrocortisone sodium succinate : 1 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254	
	Hydrocortisone sodium succinate : 1 mg/ml Teniposide : 0.1 mg/ml		905	
	Hydrocortisone sodium succinate : 2 mg/ml Theophylline : 4 mg/ml		317	
		Hydrocortisone sodium succinate : 125 mg/ml Thiopental sodium : 25 mg/ml		3767
	Hydrocortisone sodium succinate : 1 mg/ml Thiotepa : 1 mg/ml		249	
		Hydrocortisone sodium succinate Vancomycin hydrochloride		3588
	Hydrocortisone sodium succinate : 1 mg/ml Vecuronium bromide : 0.1 mg/ml		402	
	Hydrocortisone sodium succinate : 0.2 mg/ml Verapamil hydrochloride : 0.08 mg/ml		1057	
	Hydrocortisone sodium succinate : 1 mg/ml Vinorelbine tartrate : 1 mg/ml		84	



## Voie d'administration



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
31	Revue	Zhang Y, Xu QA, Trissel LA, Gilbert DL. Physical and chemical stability of methotrexate sodium, cytarabine, and hydrocortisone sodium succinate in Elliott's B solution. Hosp Pharm 1996 ; 31: 965-970.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.

62	Revue	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
73	Revue	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
93	Revue	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
132	Revue	Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
211	Revue	Strom JG, Miller SW. Stability and compatibility of methylprednisolone sodium succinate and cimetidine hydrochloride in 5% dextrose injection. Am J Hosp Pharm 1991 ; 48: 1237-1241.
215	Revue	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.

249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	Revue	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
317	Revue	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Revue	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
384	Revue	Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632.
397	Revue	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
398	Revue	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
402	Revue	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.

479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
491	Revue	Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
631	Revue	Das Gupta V, Stewart KR. Chemical stabilities of hydrocortisone sodium succinate and several antibiotics when mixed with metronidazole injection for intravenous infusion. J Parenter Sci Technol 1985 ; 39: 145-148.
738	Revue	Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584.
739	Revue	Cradock JC, Kleinmann LM, Rahman A. Evaluation of some pharmaceutical aspects of intrathecal methotrexate sodium, cytarabine and hydrocortisone sodium succinate. Am J Hosp Pharm 1978 ; 35: 402-406.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
939	Revue	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1028	Revue	Cheung YW, Vishnuvajjala BR, Flora KP. Stability of cytarabine, methotrexate sodium, and hydrocortisone sodium succinate admixtures. Am J Hosp Pharm 1984 ; 41: 1802-1806.
1035	Revue	Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132.
1057	Revue	Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207.
1085	Revue	Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989 ; 173: 91-92.
1200	Revue	Chaudry IA, Bruey KP, Hurlburt LE, Oden EM. Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives. Am J Hosp Pharm 1981 ; 38: 1737-1742.
1228	Revue	Allen LV, Stiles ML. Compatibility of various admixtures at Y-injection sites of intravenous administration sets. Part2. Am J Hosp Pharm 1981 ; 38: 380-381.



1232	Revue	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1259	Revue	Jhunjhunwala VP, Bhalla HL. Compatibility of aminophylline with hydrocortisone sodium succinate or dexamethasone sodium phosphate in 5% dextrose injection. Am J Hosp Pharm 1981 ; 38: 900-901.
1315	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	Revue	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254.
1496	Revue	Trissel LA, Martinez JF, Gilbert DL. Screening cladribine for Y-site physical compatibility with selected drugs. Hosp Pharm 1996 ; 31: 1425-1428.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1661	Revue	Trissel LA, King KM, Zhang Y, Wood AM. Physical and chemical stability of methotrexate, cytarabine, and hydrocortisone in Elliott's B Solution for intrathecal use. J Oncol Pharm Practice 2002 ; 8: 27-32.
1662	Revue	Trissel LA, Saenz CA, Ingram DS, Ogundele AB. Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs. J Oncol Pharm Practice 2002 ; 8: 33-37.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.

1822	Revue	Trissel LA, Seanz C. Physical compatibility of antithymocyte globulin (rabbit) with heparin sodium and hydrocortisone sodium succinate. Am J Health-Syst Pharm 2003 ; 60: 1650-1652.
1888	Revue	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1944	Revue	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1964	Revue	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2001	Revue	Rigge DC, Jones MF. Shelf lives of aseptically prepared medicines - stability of hydrocortisone sodium succinate in PVC and non-PVC bags and in polypropylene syringes. J Pharm Biomed Anal 2005 ; 38: 332-336.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2109	Revue	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2354	Revue	Das Gupta V, Ling J. Stability of hydrocortisone sodium succinate after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2000 ; 4, 5: 396-397.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.

3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3267	Laboratoire	Lipomed Laboratories Dacarbazine Lipomed - Summary of Product Characteristics Lipomed 2011
3372	Revue	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3379	Revue	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3545	Laboratoire	Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009
3564	Laboratoire	Rocuronium B Braun - Résumé des caractéristiques du produit. B Braun 2012
3571	Revue	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3580	Laboratoire	Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016
3588	Laboratoire	Vancomycine (Vancocin®) - Résumé des caractéristiques du produit Sandoz 2011
3594	Laboratoire	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3604	Laboratoire	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3605	Laboratoire	Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit Lipomed 2010
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.

3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3838	Laboratoire	Magnesium Sulphate - Summary of Product Characteristics Martindale Pharmaceuticals Ltd 2007
3879	Revue	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4154	Laboratoire	Bleomycin sulfate- Summary of Product Characteristics Accord Health Care 2018
4254	Revue	D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4411	Revue	Wilder A.G, Foushee J.A, Fox L.M, Navalle J, Wright A.M, Greer M.A. Physical Compatibility of Medications Used in Critically Ill Patients with Balanced Fluid Solutions. Int J Pharm Compound 2020 ;24,3:238-241.
4433	Revue	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4465	Revue	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61


4550	Revue	Semark, A.J, Venkatesh, K, McWhinney B.C, Pretorius, C, Roberts, J.A, Cohen J, Venkatesh B. The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration. Crit Care Resusc 2013 ;15, 1: 63–66.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4641	Revue	Zanon D, Selmin F, Centin G, Maximova N, Casiraghi A, Minghetti P. Stability of high concentrated triple intrathecal therapy for pediatrics and mitigation strategies. Eur J Pharm Sci 2021 ;167: 106039.
4698	Revue	Ayari G, D&#39;Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4776	Revue	Tomczak S, Chmielewski, M, Szkudlarek J, Jelińska A. Antiemetic Drugs Compatibility Evaluation with Paediatric Parenteral Nutrition Admixtures. Pharmaceutics 2023 ; 15: 2143.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



# Stabilis



## Hydrocortisone sodium succinate



### Stabilité des préparations

100 mg Hydrocortisone Upjohn®		Acide citrique 200 mg Eau purifiée >> 100 mL NaOH 1N >> pH 5,5	3-7°C		21			4416
100 mg Hydrocortisone Upjohn®		Acide citrique 200 mg Eau purifiée >> 100 mL NaOH 1N >> pH 6,5	3-7°C		21			4416
100 mg Hydrocortisone Upjohn®		Eau ppi >> 100 mL Acide chlorhydrique 1N >> pH 4	3-7°C		14			4416



### Bibliographie

	Type	Source
4416	Revue	Chappe J, Osman N, Cisternino S, Fontan J-E, Schlatter J. Stability of Hydrocortisone Preservative-Free Oral Solutions. J Pediatr Pharmacol Ther 2015 ; 20, 3: 197-202.



# Dictionnaire

Antiinflammatoire	Injectable
Noms commerciaux	Stabilité des solutions
Contenant	Molécule
Concentration	Température
Conservation	Durée de stabilité
Biosimilaire	Données conflictuelles
Bibliographie	Verre
Chlorure de sodium 0,9%	Lumière
Jour	<b>RL</b> Ringer lactate
<b>EI B</b> Solution d'Elliott B	Heure
Non précisée	A l'abri de la lumière
Polyvinyl chlorure	Polyoléfine
Seringue polypropylène	Eau pour préparation injectable
Stabilité en mélange	Solvant
Molécule	Aucun
NaCl 0,9% ou glucose 5%	Compatibilités
Compatible	Glucose 5%
Instabilité chimique	Incompatible
Incompatibilité non précisée	Précipitation immédiate
Précipitation en 4 heures	Turbidité immédiate
Nutrition parentérale (mélange binaire)	Turbidité en 1 heure
Nutrition parentérale (mélange ternaire)	NaCl 0,9% + bactériostatique
Solvant spécifique	Modification du pH > 1 unité pH
Précipitation en 15 minutes	Précipitation en 1 heure
Voie d'administration	Intraveineuse
Perfusion intraveineuse	Intramusculaire
Bibliographie	Solution buvable
Stabilité des préparations	Origine
Excipient	Flacon injectable
Dictionnaire	